GU Cancers 2019 | CheckMate 214 trial in RCC updates

David McDermott

Prof. David McDermott, MD, of Beth Israel Deaconess Medical Center, Boston, MA, discusses results from the Phase III Checkmate 214 trial, which brought PD1 blockers into the frontline of renal cell carcinoma (RCC) treatment. Prof. McDermott explained that nivolumab administration in combination with ipilimumab improved previously untreated RCC overall survival, when compared with sunitinib. This video was recorded at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video  
Similar topics
Related videos
1:45
Potential role of rituximab in mCRPC
Lisa Holle
4:06
Cancer treatment: major milestones & what's next in the 2020s
John Wagstaff
3:01
Preliminary findings in mCRPC for fractionated dose 177Lu-PSMA-617
Scott Tagawa
1:36
Urothelial carcinoma: apatorsen plus docetaxel does not provide significant value
Petros Grivas
2:33
irAEs with single-agent PD-1 vs PD-L1 inhibitors
Petros Grivas
Genitourinary Cancer, Kidney Cancer
Checkpoint Inhibitors, Ipilimumab, Nivolumab, Sunitinib
CheckMate 214
GU Cancers 2019
Interview
15th February 2019
More from David McDermott
RCC treatment: future remarks
Recent immunotherapy advances in RCC
vjoncology logo VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals